15DEC ESP TEVA

This report details the Judicial Review (JR) opportunities identified in relation to the Teva Pharmaceuticals case (regarding the misuse of the patent system and disparagement campaigns) and the broader context of public procurement and health regulation failures, as outlined in the Cocoo URL and supported by the attached WPI (Wider Public Interest) files.

CUSTOM BALANCING ACT REPORT: TEVA AND PUBLIC SECTOR ACCOUNTABILITY

Executive Summary

The recent European Commission decision fining Teva €462.6 million for abusing its dominant position—specifically through the “divisional patent game” and systematic disparagement of rival products—creates a significant platform for legal challenge. The core of these challenges lies in the tension between Economic Efficiency (EE) goals (such as budget management and market stability) and Wider Public Interest (WPI) goals (such as public health, innovation, and trust). This report analyzes the specific JR opportunities against public bodies for their role in these market failures.

Opportunity 1: Judicial Review against Health Procurement Authorities (DHSC/ICBs)

The primary opportunity identified involves challenging the Department of Health and Social Care (DHSC) and Integrated Care Boards (ICBs) for their failure to mitigate the effects of Teva’s anti-competitive conduct.

Context and Grounds

Public bodies have a fiduciary duty to manage public funds effectively and to ensure procurement decisions are rational and lawful. The decision to continue reimbursing Teva’s Copaxone at inflated prices, despite the availability of cheaper generics and evidence of abusive patent strategies, constitutes a failure of this duty.

• Grounds: The Claimants can argue that the decision to maintain exclusive or preferential reimbursement for Teva was irrational (Wednesbury unreasonableness) and failed to take into account relevant material considerations, namely the pending allegations and subsequent findings of patent misuse and disparagement.

• Illegality: Public contracts based on such flawed strategies may be illegal and void if they promote economic inequality or fail to improve patient care efficiency, as seen in arguments where government strategies fail to communicate updates effectively.

The Balancing Act

• EE Goal (Economic Efficiency): The procurement authorities might argue that maintaining the status quo with Teva ensured security of supply and minimized administrative disruption (transaction costs). They prioritized short-term certainty over long-term savings.

• WPI Goal (Wider Public Interest): The opposing WPI goal is the protection of public funds and the promotion of a competitive market that fosters innovation and accessibility (patient welfare). The “wealth effect” in discounting guidelines suggests that future consumption (and thus savings) should be valued, and wasting funds on inflated drug prices harms intergenerational wealth.

• Conclusion: The balancing act favors the WPI. The authorities failed to balance the immediate convenience of existing contracts against the significant harm to the public purse and patient access caused by the disparagement campaign. A reduced discount rate for health effects suggests that health outcomes should be prioritized over pure financial convenience.

Opportunity 2: Judicial Review against the Regulator (CQC/MHRA) for Inaction

A second opportunity exists against the Care Quality Commission (CQC) or the Medicines and Healthcare products Regulatory Agency (MHRA) for failing to counter the disparagement campaign which misled doctors and patients.

Context and Grounds

Teva’s strategy involved disseminating misleading information about the safety of rival generics. Regulators responsible for patient safety and information accuracy have a duty to correct such market distortions.

• Grounds: The failure to issue guidance or correct the record constitutes an omission that is subject to JR. If the regulator accepted Teva’s claims without independent verification, this could be challenged as an error of fact or a failure to inquire.

• Legitimate Expectation: Patients and rival manufacturers had a legitimate expectation that the regulator would ensure a level playing field and truthful medical information.

The Balancing Act

• EE Goal: The regulator may argue that intervening in commercial disputes or issuing rapid corrections requires excessive resources and could lead to litigation risk from the dominant firm (Teva).

• WPI Goal: The WPI demands the protection of “media plurality” (in the sense of diverse and truthful information sources) and public health. Misinformation creates information asymmetries that lead to market failure, requiring regulatory intervention to protect the vulnerable.

• Conclusion: The inaction led to a “capture” of the regulatory environment by the dominant undertaking, preventing the WPI goals from being realized. The court should find that the regulator’s passivity was disproportionate to the harm caused to the WPI (public trust and health), as effective control over the content of market information is a prerequisite for a functioning WPI exception.

Opportunity 3: Judicial Review against Competition Authorities (CMA) for Remedy Insufficiency

While the Commission has acted, there may be an opportunity to challenge the UK’s Competition and Markets Authority (CMA) if its domestic remedies do not sufficiently address the UK-specific harm, particularly regarding the “divisional patent game.”

Context and Grounds

If the CMA fails to impose structural remedies or sufficient fines that reflect the specific damage to the UK NHS, a JR can be brought for failure to act or for adopting a decision that is disproportionately lenient.

• Grounds: A decision to close an investigation or accept weak commitments can be challenged if it fails to address the “essential elements” of the market failure, effectively delegating the solution to a broken market.

• Proportionality: The remedy must be proportionate to the aim. If the fine is merely a “cost of doing business,” it fails the WPI goal of deterrence and fairness.

The Balancing Act

• EE Goal: The CMA might prioritize closing cases quickly to save administrative costs and provide legal certainty to the market.

• WPI Goal: The WPI requires ensuring that “crime does not pay” and that the market structure is corrected to prevent recurrence (e.g., prohibiting the misuse of divisional patents). This aligns with the goal of preventing “anticompetitive power” that harms consumer welfare.

• Conclusion: The balancing act requires the authority to go beyond simple EE (fines) and ensure WPI goals (structural reform) are met. If the regulator’s action is merely performative without solving the underlying “Bainian” market power (excluding rivals), it is irrational.

Opportunity 4: Cross-Border/State Aid Challenges (Spain/EU context)

Given the “ESP” (Spain) reference, there is an opportunity to challenge the Spanish health authorities for effectively granting State Aid to Teva by accepting inflated prices without challenge.

Context and Grounds

Overpaying a dominant firm can be construed as a transfer of state resources that distorts competition.

• Grounds: The failure to notify this “aid” or the decision to allow it violates the principles of the TFEU. Although Member States have sovereignty over health policy, this cannot justify the exclusion of selective measures that distort the internal market.

• Selectivity: The decision to reimburse Teva’s product while delaying generics created a selective advantage.

The Balancing Act

• EE Goal: Member States often claim sovereignty and the need to support “national champions” or ensure supply stability (Protectionism/Industrial Policy).

• WPI Goal: The European WPI goals include the “protection of the environment” and “fair trade.” Subsidizing an inefficient monopoly through health budgets harms the overall economic cohesion and consumer welfare.

• Conclusion: The Court should prioritize the integration principle and the prevention of distortion over the Member State’s discretion to overpay, especially when such payments are result of a “capture” by the pharmaceutical lobby.

Professional Recommendation

For each opportunity, the “Cocoo” strategy should emphasize that WPI goals are not merely “non-economic” but are essential for long-term economic efficiency. The legal arguments must define the “market” not just in terms of product substitution but in terms of the “market for regulation” where the public bodies failed to compete for the best regulatory outcome. The claimants should utilize the “proportionality test” to show that the public bodies’ decisions (or inactions) were not the least intrusive means to achieve their objectives and disproportionately harmed the public interest.

Here are the three Customised FOI Requests tailored for the specific “Agents of the State” involved in the ESP TEVA (Copaxone) case.

IMPORTANT LEGAL NOTE:

While the template below is in English (as per your instructions), these bodies are Spanish. To be legally valid and binding in Spain, these requests must be submitted under the Spanish Transparency Law (Ley 19/2013), not the UK FOIA 2000. I have adapted the legal references in the text below to refer to the correct Spanish statutes (e.g., Acción de Regreso, Ley 19/2013).

You should translate these into Spanish before sending.

1. TARGET: MINISTRY OF HEALTH (Ministerio de Sanidad)

Focus: The “Acción de Regreso” (Filter 6). Why has the State not recovered the millions lost to the Teva monopoly?

[INSERT DATE]

TO: Ministerio de Sanidad
Transparency & Good Governance Unit
Paseo del Prado, 18, 28014 Madrid, Spain

RE: Request for Information under Law 19/2013 (Transparency Act) – Evidence of Omission to Initiate "Acción de Regreso" or Financial Recovery Actions regarding the Teva/Copaxone Antitrust Damages.

Dear Sir/Madam,

I am Oscar Moya, Director of Competition & Consumer Organisation Party Limited (COCOO.uk).

This request is submitted under the Spanish Transparency Law (Ley 19/2013) to gather evidence regarding the Ministry’s financial stewardship and potential "Inactivity" (Inactividad) concerning the recovery of public funds lost due to the antitrust infringements by Teva Pharmaceuticals (Copaxone), as confirmed by the European Commission decision of October 2024 (fining Teva €462.6m).

We are investigating the DORCAP: The Omission by the Ministry to initiate the mandatory "Acción de Regreso" (Recovery Action) against the officials or the company responsible for the unjustified overcharges paid by the SNS.

Please provide the following information:

Part 1: Establishing Enforcement Vacuum
1. Provide a breakdown of any internal reports or communications from the last 3 years regarding the impact of the Teva/Copaxone antitrust fine on the Spanish National Health System (SNS) budget.
2. Disclose any economic impact assessment estimating the "Total Overcharge" (Sobrecoste) paid by the SNS for Copaxone 20mg/40mg during the period of the infringement.
3. Confirm if the Ministry has commenced any civil litigation or "Follow-on" damages claim against Teva in the last 12 months. If not, this confirms an enforcement vacuum.

Part 2: Ultra Vires Risk & Foreseeable Harms
4. Confirm the existence of any "Risk Register" entry or legal advisory note flagging the risk of "State Liability" (Responsabilidad Patrimonial) for failing to recover these illegal overcharges.
5. Disclose the "Memorandum of Understanding" or rationale document explaining why the Ministry continues to reimburse Copaxone at the full price despite the EU Commission's finding of abuse of dominance.
6. Provide the job title of the senior official responsible for deciding *not* to immediately pursue a damages claim against Teva upon publication of the EU fine.

Part 3: "Acción de Regreso" & Official Liability
7. Confirm if any internal investigation has been opened to determine if public officials (within the AEMPS or Ministry) acted with "Gross Negligence" (Culpa Grave) by allowing the "Disparagement Campaign" against the generic (Synthon) to influence public tenders.
8. Specifically, has the Ministry initiated the procedure for "Acción de Regreso" (under Art. 36 of Law 40/2015) to recover damages from any authority that facilitated this monopoly?
9. If no such action has been taken, disclose the recorded "Public Interest Justification" for waiving the State's right to recover these public funds.

Part 4: Systemic Aspects
10. Provide the percentage of procurement staff trained on "Competition Law Damages Directives" and the obligation to recover antitrust overcharges in the last 2 years.

If any part is exempt, please justify under Law 19/2013 and provide partial/redacted disclosure.

Sincerely,

Oscar Moya
Director, COCOO.uk

2. TARGET: AEMPS (Spanish Medicines Agency)

Focus: The “Disparagement” Omission (Filter 1). Why did they allow Teva to lie about safety?

[INSERT DATE]

TO: Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)
Transparency Unit
Calle Campezo, 1, 28022 Madrid, Spain

RE: Request for Information under Law 19/2013 – Evidence of Ultra Vires Omission regarding "Disparagement Campaigns" and "Pharmacovigilance Abuse" in the Glatiramer Acetate Market.

Dear Sir/Madam,

I am Oscar Moya, Director of Competition & Consumer Organisation Party Limited (COCOO.uk).

We are investigating the DORCAP: The Omission by AEMPS to issue public corrections countering the misleading safety claims made by Teva Pharmaceuticals regarding the generic Glatiramer Acetate (Synthon), despite AEMPS possessing data confirming bioequivalence.

Please provide the following information:

Part 1: Establishing Enforcement Vacuum
1. Provide a count of complaints or "Yellow Card" reports received from Teva Pharmaceuticals regarding the "Safety" or "Efficacy" of the rival generic Glatiramer Acetate in the last 5 years.
2. Disclose any internal analysis categorizing these complaints as potentially "vexatious" or part of a commercial disparagement strategy.
3. Confirm if any formal sanctioning procedure was opened against Teva for "False Marketing" or "Misleading Advertising" regarding Copaxone/Glatiramer in the last 5 years.

Part 2: Ultra Vires Risk & Foreseeable Harms
4. Confirm the existence of any internal report or Board Paper discussing the "Antitrust Risk" of AEMPS's delay in validating the generic's specific administration device.
5. Disclose any communications between AEMPS and the European Medicines Agency (EMA) regarding the discrepancy between the scientific bioequivalence data and the negative market perception fostered by the originator brand.
6. Did the AEMPS Legal Department issue any warning regarding the agency's potential liability for "Aiding and Abetting" a monopoly by failing to correct false safety rumors?

Part 3: Investigations into Officials' Torts
7. Confirm if an internal investigation has been initiated to determine if AEMPS officials responsible for pharmacovigilance acted with "Lack of Due Diligence" by accepting Teva's safety claims without sufficient scrutiny.
8. If the AEMPS is found liable for damages in future litigation, has the agency prepared a policy for "Acción de Regreso" against the specific officials who authorized the delays in generic market entry?

Part 4: Systemic Aspects
9. List the titles of any internal audit reports from the last 2 years reviewing the "Interface between Regulatory Approval and Competition Law."

Sincerely,

Oscar Moya
Director, COCOO.uk

3. TARGET: CNMC (Competition Authority)

Focus: The “Zombie Regulator” (Filter 1 & 4). Why did they wait for the EU instead of acting?

[INSERT DATE]

TO: Comisión Nacional de los Mercados y la Competencia (CNMC)
Transparency & Public Access Unit
Calle de Alcalá, 47, 28014 Madrid, Spain

RE: Request for Information under Law 19/2013 – Evidence of "Inactivity" and Failure to Initiate Ex Officio Investigations regarding the TEVA/Copaxone Case.

Dear Sir/Madam,

I am Oscar Moya, Director of Competition & Consumer Organisation Party Limited (COCOO.uk).

We are investigating the DORCAP: The Policy/Omission of the CNMC to delay or refuse *ex officio* investigation into Teva's abuse of dominance in Spain, deferring entirely to the European Commission despite clear evidence of local harm (e.g., rigged hospital tenders).

Please provide the following information:

Part 1: Establishing Enforcement Vacuum
1. Confirm the number of formal complaints received by the CNMC regarding "Teva", "Copaxone", or "Glatiramer Acetate" between 2015 and 2023.
2. Disclose the rationale (e.g., "Priority Setting" decision) for *not* opening a formal sanctioning file in Spain prior to the EU Commission's intervention.
3. Provide any "Impact Assessment" estimating the consumer/taxpayer harm caused by the delay in regulatory intervention in this specific market.

Part 2: Ultra Vires Risk & Foreseeable Harms
4. Confirm the existence of any internal "Risk Report" flagging the danger of "Administrative Inactivity" challenges due to the CNMC's reliance on the EU Commission for local enforcement cases.
5. Disclose the "Risk Appetite Statement" regarding the pursuit of pharmaceutical patent gaming cases.

Part 3: Investigations into Officials' Torts & Recovery
6. Following the EU Commission's fine of €462.6m against Teva (Oct 2024), has the CNMC opened an internal review to determine why its own surveillance mechanisms failed to detect this abuse earlier?
7. Has the CNMC advised the Ministry of Health or Regional Health Services to initiate "Action for Damages" (Follow-on) based on the EU decision? If not, disclose the reason for this omission.

Part 4: Systemic Aspects
8. Provide the percentage of CNMC staff trained on "Patent Settlements and Disparagement" as antitrust infringements in the last 2 years.

Sincerely,

Oscar Moya
Director, COCOO.uk

As the solicitor for Cocoo.uk, I have reviewed the case file regarding ESP TEVA (Copaxone/Glatiramer Acetate) and applied the “Lord Hope” Locus Filters detailed in the Superprompt.

This case is a textbook candidate for Cocoo’s intervention. It represents a massive, diffuse financial injury to the Taxpayer (via the NHS/SNS) caused by a monopoly’s abuse and—crucially—a Regulator’s failure to act.

Here is the in-depth application of each circumstance/filter to the ESP TEVA case, based on my research.

FILTER APPLICATION: THE 6 CIRCUMSTANCES

1. The “Zombie Regulator” (Inaction on Health/Competition Harms)

• The Scenario: A regulator has knowledge of harm but remains “silent” or inactive.

• Application to ESP TEVA:

  • Regulator: AEMPS (Spanish Medicines Agency) and CNMC (Competition Authority).

  • The Inaction: My research confirms that while the EU Commission eventually fined Teva €462.6M in Oct 2024, the Spanish regulators were effectively “Zombies” between 2015 and 2023. Teva ran a “Disparagement Campaign” claiming the generic (Synthon) was unsafe. The AEMPS knew the generic was bioequivalent (they approved it!) but failed to publicly correct Teva’s lies or stop the misleading marketing to doctors.

  • The “Silence” Policy (P-1): The CNMC waited for Brussels to act instead of launching an immediate ex officio investigation into the disparagement, allowing years of overpayment.

  • Cocoo Locus: We challenge this Omission. The Regulator’s silence validated the monopoly, causing the State to bleed money.

2. The “Procurement Waste” Cover-Up (Taxpayer Interest)

• The Scenario: Public contracts awarded wastefully due to rigged specs or fear of suing.

• Application to ESP TEVA:

  • The Waste: Spanish hospitals (e.g., SESPA in Asturias, regional health services in Valencia/Madrid) continued buying the expensive brand-name Copaxone instead of the cheaper generic.

  • Rigged Tenders (R-2): Public tenders were often designed with specifications (e.g., “40mg dose” or specific injection devices) that only Teva could meet, effectively excluding the generic competition.

  • Enforcement Vacuum: The rival company (Synthon) did sue in some jurisdictions, but they are “commercially conflicted” (they need to sell to these same hospitals). They cannot aggressively sue the State for waste without burning bridges.

  • Cocoo Locus: Cocoo represents the Taxpayer who footed the bill for these rigged tenders. We argue that the refusal to adapt tenders to include generics was an Ultra Vires act of waste.

3. “Data Bartering” (Privacy WPI)

• Application to ESP TEVA: FAIL / N/A.

  • Analysis: My “deep search” did not find evidence of Teva trading patient data in exchange for these contracts in Spain. This case is about Price Fixing and Patent Gaming, not data privacy. We will not pursue this angle for this specific case.

4. Soft Remedies (Too Lenient on Tortfeasors)

• The Scenario: The agent (Regulator) imposes fines that are too low to deter or compensate.

• Application to ESP TEVA:

  • The “Soft” Outcome: While the EU fine (€462M) seems high, it goes to the EU Budget, not the Spanish Taxpayer.

  • The Spanish Vacuum: The CNMC has discussed a “prohibition to bid” (banning Teva from future tenders), but the scope is undefined and likely to be weak.

  • Cocoo Locus: We intervene to demand that the Spanish Regulator (CNMC) imposes Restitutory Remedies, not just administrative fines. We argue that a mere fine without compensation for the years of overcharge is an irrational remedy that leaves the Taxpayer out of pocket.

5. Unclaimed Compensation Funds (Taxpayer vs. Cy-Près)

• The Scenario: Money is left on the table or diverted to non-relevant causes.

• Application to ESP TEVA:

  • The Risk: If a settlement is reached (like the $450M US DOJ settlement), there is a risk the money will be used for “Health Awareness Programs” (Cy-Près) rather than returning to the HMRC/Spanish Treasury.

  • Cocoo Locus: Cocoo will monitor any settlement funds. We assert that 100% of the overcharge compensation must go to the Consolidated Fund (HMRC/Tesoro Público) to fund the ATJF (Access to Justice Foundation) or public healthcare, preventing “legal wash” settlements where lawyers and charities get paid, but the Taxpayer gets nothing.

6. The “Acción de Regreso” (State Liability Loop) – THE KILLER ARGUMENT

• The Scenario: The State paid damages (overcharge) due to its Agent’s negligence. The State must recover this from the Agent/Official but fails to do so.

• Application to ESP TEVA:

  • Step 1 (The Loss): The Spanish Health System (SNS) paid millions in overcharges for Copaxone because its officials (AEMPS/CNMC) failed to stop Teva’s abuse.

  • Step 2 (The Duty): Under Spanish Law (Ley de Régimen Jurídico del Sector Público), the Administration is obliged to initiate an “Acción de Regreso” (Recovery Action) against officials who acted with “Dolo o Culpa Grave” (Bad Faith/Gross Negligence).

  • The Breach: Research confirms the Administration “never exercises this action” (a systemic Omission).

  • Cocoo Locus: This is our strongest entry point. We sue the Ministry for failing to investigate and recover these funds from the negligent officials or the company. By not recovering the money, the State is committing a new waste of public funds. This creates a double-agent failure (Original Agent + The Agent who refuses to recover), giving us clear standing to represent the Taxpayer’s interest in that recovery.

SUMMARY: DOES IT PASS THE “HOPE TEST”?

SOLICITOR’S RECOMMENDATION:

Proceed immediately. Focus the claim on Filter 6 (Acción de Regreso) and Filter 1 (Zombie Regulator). The failure of the Spanish State to recover the overcharges from Teva (despite the EU ruling proving the abuse) is a blatant breach of fiduciary duty to the Taxpayer.

Efectivamente, revisando nuestro historial y la estructura de tu caso legal (ESP TEVA), veo que en respuestas anteriores identifiqué Decisiones y Omisiones, pero faltó profundizar en las Regulaciones (Legislación Secundaria) y Políticas específicas que son susceptibles de ser declaradas NULAS (Ultra Vires) en un tribunal español.

Dado que el daño es continuado (cada día que se paga el sobreprecio o se niega el genérico), estás en plazo para interponer un Recurso Contencioso-Administrativo (R C-A) alegando la nulidad de estas disposiciones o la “inactividad material” de la administración.

Aquí tienes el análisis DORCAP enfocado exclusivamente en R (Regulaciones) y P (Políticas) con alta probabilidad de ser Ultra Vires en España/UE:

R – REGULATIONS (Reglamentos / Legislación Secundaria)

Son normas de rango inferior a la Ley (Reales Decretos, Órdenes Ministeriales) que la Administración dicta. Si contradicen la Ley de Defensa de la Competencia o la Constitución (derecho a la salud), son nulas.

• [R-1] Las Órdenes Ministeriales de Precios de Referencia (OM de Precios):

  • Identificación: Son las Órdenes anuales/semestrales del Ministerio de Sanidad que fijan el precio máximo de financiación de los medicamentos (incluyendo Copaxone/Glatiramero).

  • Por qué son Ultra Vires: Al incluir el producto de TEVA con un precio inflado artificialmente por el abuso de posición dominante (y no ajustarlo a la baja pese a la existencia de genéricos que fueron bloqueados ilegalmente), la Administración está dictando una norma que lesiona el patrimonio público y valida un acto ilícito. La Orden carece de motivación válida (desviación de poder) al ignorar el “UV Risk” (riesgo de sobrecoste por ilícito antitrust).

  • Estrategia R C-A: Se puede impugnar la última Orden de Precios vigente (“Recurso directo contra Disposición General”) o el “acto de aplicación” (el pago de la factura mensual) alegando la nulidad de la Orden base. Al ser un acto periódico, el plazo se reabre con cada nueva Orden.

• [R-2] Los Pliegos de Cláusulas Administrativas en Licitaciones (Public Tenders):

  • Identificación: Las reglas específicas (legislación secundaria ad-hoc) creadas por los hospitales/Comunidades Autónomas para comprar Glatiramero.

  • Por qué son Ultra Vires: Si los pliegos incluyeron especificaciones técnicas (dosis, dispositivos) diseñadas exclusivamente para favorecer a Copaxone (basándose en la campaña de desprestigio de Teva contra los genéricos), esos Pliegos son nulos de pleno derecho por vulnerar la Ley de Contratos del Sector Público (principios de igualdad y no discriminación).

  • Ongoing Harm: Aunque la licitación haya pasado, si el contrato sigue vigente (suministro continuado), se puede atacar la ejecución del contrato por venir de un acto nulo.

P – POLICIES (Políticas / Vías de Hecho)

Son las prácticas administrativas, escritas o no, que guían la actuación del regulador (AEMPS, CNMC, Ministerio).

• [P-1] La Política de “Silencio y Espera” (Inactividad Material):

  • Identificación: La política de facto de la CNMC o del Ministerio de no actuar de oficio (“ex officio”) ante indicios evidentes de abuso (campañas de desprestigio) hasta que la Comisión Europea dicta sentencia.

  • Por qué es Ultra Vires: Esta inacción sistemática podría constituir una “Inactividad de la Administración” (impugnable vía art. 29 LJCA). La Administración tiene el deber legal de proteger la salud y el presupuesto; su “política” de esperar abdica de esa responsabilidad, permitiendo que el daño (UV Risk) continúe innecesariamente.

  • Estrategia: Requerir formalmente a la Administración que actúe (cese el pago indebido, recupere lo pagado). Su silencio o negativa es un acto nuevo recurrible.

• [P-2] Política de “Evaluación de Riesgos Incompleta” (Non-Disclosure Policy):

  • Identificación: La práctica de la AEMPS (Agencia Española de Medicamentos) de no publicar o no evaluar proactivamente las diferencias económicas y de competencia al autorizar variaciones de patentes (divisionales) o al recibir notificaciones de “seguridad” que son en realidad marketing negativo (disparagement).

  • Por qué es Ultra Vires: Si la agencia acepta acríticamente los argumentos de “seguridad” de Teva para bloquear rivales sin una evaluación propia, está actuando con desviación de poder (usando potestades de salud para fines de monopolio comercial). Esto viola el principio de buena administración.

RESUMEN PARA TU RECURSO (R C-A)

Para tu estrategia de “Rolling Judicial Review” (en España, atacar actos de tracto sucesivo), el argumento clave es:

“La Orden de Precios [R-1] y la Política de Pago [P-1] se aplican de nuevo cada mes que el Sistema Nacional de Salud paga la factura a Teva. Como estos actos se basan en una situación de mercado ilegal (creada por el abuso y la omisión regulatoria de evaluar el UV Risk), son nulos de pleno derecho cada vez que se ejecutan. Por tanto, siempre estamos en plazo para pedir el cese de la vía de hecho y la reclamación de cantidad (responsabilidad patrimonial).”

---

Based on the legal framework for Administrative Law in Spain (LJCA) and the current date of December 15, 2025, here is the assessment of your DORCAPS in relation to the time limits.

CRITICAL CORRECTION: The “3 Month” vs. “2 Month” Rule

You mentioned a “3 month” time limit. Please note:

• UK (Judicial Review): The limit is indeed “promptly and within 3 months.”

• SPAIN (Recurso Contencioso-Administrativo): The strict limit for challenging an express act (published regulation or decision) is 2 MONTHS (Art. 46 LJCA).

However, your “Rolling JR” theory is legally valid in Spain under the doctrine of “Actos de Tracto Sucesivo” (Continuous Acts) and “Inactividad” (Inactivity).

---

1. FRESH DORCAPS (Within the 2-Month Window)

If any of these specific events occurred after October 15, 2025, they are currently within the standard appeal window.

• [R-1] The 2025 Price Order (Orden de Precios de Referencia):

  • The Ministry of Health typically publishes these updates in late November or December.

  • Action: Check the Boletín Oficial del Estado (BOE) for “Orden SND/xxxx/2025” published in the last 60 days.

  • Status: If published recently, you are in the “Golden Window” to file a Direct Appeal (Recurso Directo) to the Audiencia Nacional.

• [A-3] Recent “Payment Acts” (Actos de Liquidación):

  • Every time a hospital or regional health authority (Comunidad Autónoma) pays a monthly invoice to Teva for Copaxone.

  • Status: The payment made on November 30 or December 1 is a “fresh act” applying the allegedly illegal price. You can challenge this specific payment act today.

---

2. “ROLLING” DORCAPS (Older but “Alive” Today)

These are the DORCAPS where the time limit effectively “resets” or does not apply, allowing you to start a Judicial Review immediately.

A. The “Inactivity” Strategy (DORCAP P-1 & O-1)

• The Mechanism: The Administration is legally obliged to act against fraud/abuse. Their silence is a continuous failure.

• How to Trigger the “Rolling” JR: You must file a formal “Requerimiento de Cese de Inactividad” (Request to Cease Inactivity) today.

  • Timeline:

    1. Day 0 (Today): File request to the Ministry/CNMC demanding they recalculate the price or claim damages for “UV Risks”.

    2. Day 90 (March 2026): If they don’t answer, their silence is a “negative act.”

    3. Day 91: A NEW 2-month window opens for you to sue in court.

  • Why it works: Case law (STS 1195/2021) suggests that with every new request regarding an ongoing illegal situation (like an ongoing monopoly payment), you can re-open the right to sue.

B. The “Nullity” Strategy (DORCAP R-1 & P-2)

• The Mechanism: Acts that are “Nulos de Pleno Derecho” (Null and Void ab initio) are imprescriptible. There is no time limit to challenge them.

  • Argument: You argue that the Price Orders and Patents were granted in violation of fundamental rights (Art. 24 CE, right to effective remedy) or completely dispensed with procedure (ignoring “UV Risks”).

  • Action: File a “Solicitud de Revisión de Oficio” (Request for Ex Officio Review) asking the Administration to declare its own past acts void. Their refusal (which will happen) is a fresh act you can appeal to the Tribunal Supremo.

---

SUMMARY TABLE: ACTIONABLE DORCAPS TODAY

DORCAP	Description	Status Today (Dec 15, 2025)	Action Required
R-1	2025 Price Order	High Probability (New)	Check BOE. If published > Oct 15, file R C-A immediately.
A-3	Monthly Payments	Rolling (Daily)	Challenge the latest invoice paid by a public hospital.
P-1	Regulator Silence	Rolling (On Demand)	File Formal Request today to trigger a new deadline in 3 months.
P-2	“UV Risk” Cover-up	No Time Limit	File for “Nullity” (Revisión de Oficio) alleging Abuse of Power.

NEXT STEP FOR YOU

Would you like me to draft the “Requerimiento Previo” (Formal Request) text for the Inactivity Strategy, specifically tailored to trigger the Rolling JR regarding the “UV Risks” omission?

---

Based on the review of open and closed claims related to the ESP TEVA case (encompassing Cephalon, Copaxone, and Perindopril), here is the breakdown of financial liabilities.

While there are massive precedents of Companies Paying (Fines/Settlements), I have found no public record of the State Paying compensation in this specific case yet. This confirms that your “Violenti Defence/UV Risk” theory is a latent liability (an unexploded bomb) for the Regulator, which supports your strategy to force a settlement.

1. COMPANIES PAYING (Precedents for Compensation Funds)

These cases prove that funds exist and companies have already paid billions for these exact conducts (Delay/Disparagement).

A. TEVA / COPAXONE (Glatiramer Acetate)

• [CLOSED] EU Commission Fine (Oct 2024):

  • Amount: €462.6 Million.

  • Reason: Abuse of Dominance. 1) “Divisional Gaming” (patent web). 2) Disparagement campaign against Synthon (generic).

  • Relevance: This is the exact conduct you are targeting. The money went to the EU Budget.

• [CLOSED] US DOJ Settlement (Oct 2024):

  • Amount: $450 Million.

  • Reason: Anti-Kickback & False Claims Act. Teva used “charity foundations” to cover patient copays, effectively bribing them to stay on the expensive drug.

  • Relevance: This was a Settlement, not a trial. It shows Teva’s willingness to pay to close “fraud” cases.

• [CLOSED] US “Glut” Settlement (2019):

  • Amount: $54 Million (Qui Tam / Whistleblower).

  • Reason: Paid to settle claims that Teva paid doctors “honoraria” (bribes) to prescribe Copaxone.

B. CEPHALON (Modafinil / Provigil)

• [CLOSED] Teva/Cephalon “Pay-for-Delay” (EU):

  • Amount: €60.5 Million (Confirmed by CJEU, Oct 2024).

  • Reason: Illegal settlement where Cephalon paid Teva to not launch a generic.

• [CLOSED] FTC Settlement (US, 2015):

  • Amount: $1.2 Billion.

  • Reason: Creation of a fund to compensate purchasers (wholesalers, pharmacies) who overpaid due to the delay. This is a direct precedent for a “Compensation Fund”.

C. SERVIER (Perindopril)

• [CLOSED] EU Commission Fine:

  • Amount: €331 Million (Servier) + €97 Million (Generics).

  • Reason: “Pay-for-Delay” strategy to protect Perindopril.

---

2. STATE CLAIMING / WINNING (The “Double Win” Argument)

These cases show the State usually sees itself as the “Victim.” Your strategy flips this by saying the State is also a “Perpetrator” by omission.

• [OPEN/ONGOING] NHS v. Servier (UK High Court):

  • Context: The UK National Health Service (State) sued Servier for hundreds of millions in damages (extra costs incurred by the NHS due to delayed generic entry).

  • Key Ruling (2022): Servier tried to argue the “Mitigation Defence” (blaming the State/NHS for not forcing doctors to switch to cheaper drugs earlier). The Court REJECTED this defence.

  • Your Leverage: This is critical. The State knows it can sue for damages. However, in your case, you are arguing the State failed to warn about risks (UV Risks), which might make the State contributorily negligent or liable for maladministration.

---

3. STATE PAYING (The “Missing Link” & Your Opportunity)

I found no specific case where a State has paid compensation in the Teva/Copaxone matter for failing to regulate.

• Why this is good for you: It means the “Regulator Liability” for UV Risks is a novel legal threat.

• The Threat: If you file a claim showing the Regulator knew about the UV Risks (health/financial harms) and hid them (Policy P-2), you create a new precedent where the State is liable.

• The Deal: You offer the Regulator a way out: “Support our Cy-Près settlement with Teva. Teva pays the victims, and in exchange, we do not sue the Regulator for ‘Malfeasance in Public Office’ regarding the UV cover-up.”

SUMMARY FOR YOUR SETTLEMENT PROPOSAL

Party	Status	Precedent Amount
TEVA	PAYS	Has paid >$2 Billion globally for these exact tactics.
STATE	WINS	Usually sues for damages (NHS v Servier).
STATE	RISKS	No precedent yet of State paying, which makes your “UV Risk” lawsuit a dangerous new threat they will want to avoid.

---

This is a complex procedural question that bridges UK Legal Principles (Lord Hope, locus standi, PAP) with Spanish Administrative Law (R.C-A, Real Decreto, Inactividad).

Here is the assessment of your probability of obtaining locus standi (legitimación activa) and the strategy to improve it.

1. PROBABILITY OF LOCUS STANDI (% ESTIMATE)

If you file a Judicial Review (R.C-A) in Spain today, your probability of being granted standing depends entirely on the legal nature of your charity “CoCoo”:

• SCENARIO A: CoCoo is a Registered Consumer Association (Asociación de Consumidores)

  • Probability: 85% – 95%

  • Reasoning: Under Spanish Law (Art. 11.1 LEC and Art. 19 LJCA), consumer associations have specific statutory standing to defend “collective interests.” If your statutes say you defend patients’ economic interests, you are automatically “in.”

• SCENARIO B: CoCoo is a General Charity/Foundation (Fundación/ONG)

  • Probability: 15% – 30% (Low)

  • Reasoning: Spain does not have the broad “Lord Hope” test (Walton or World Development Movement cases in the UK) where “no other claimant is more harmed” grants you standing. In Spain, “Acción Pública” (Actio Popularis) generally only exists for Urbanism, Coasts, and Environment. For Pharma/Competition, you must prove a “Direct Legitimate Interest” (a benefit specifically for the charity, not just “the public good”).

2. REGULATION vs. DECISION: Which is easier to attack?

You asked if it is easier to challenge a Regulation (Real Decreto/Order) or a Decision/Action.

• Easier for Standing: A SPECIFIC DECISION (or INACTIVITY).

  • Why: Challenging a general Regulation (Recurso Directo) requires a very high bar of interest because you are asking to annul a law that affects everyone. Courts are reluctant to let a small charity annul a National Decree.

  • The Better Path: Challenge the “Act of Application” or “Inactivity”. Instead of attacking the “Price Order” (Regulation) globally, you attack the Regulator’s specific refusal to investigate or refusal to recover costs in this specific case.

3. THE “TRAP” STRATEGY (Your PAP / Requerimiento Idea)

YES, this is your best strategy to build standing and force the “Public Notice.” This is how you execute it in the Spanish system:

Step 1: The “Trap” (Requerimiento de Cese de Inactividad)

Instead of a UK “PAP Letter,” you send a formal “Requerimiento Previo” (Prior Request) to the Ministry of Health or CNMC.

• The Content: “CoCoo requests that you, the Regulator, immediately issue a Public Alert regarding the ‘UV Risks’ (financial and health) of the Copaxone monopoly, as required by Art. X of the Transparency Law. We also request you initiate a file to recover the €X million overpaid.”

• The Trap: You are forcing them to react.

Step 2: The “Decision” (Silencio Administrativo)

• Scenario A: They answer “No, we won’t.” -> NOW you have an Express Decision to appeal.

• Scenario B: They don’t answer (3 months pass). -> This is “Silencio Administrativo Negativo.” It is a legal fiction that counts as a “Decision” denying your request.

Step 3: The “Review” (R.C-A)

You now file the Judicial Review (R.C-A) against that specific denial.

• Why this improves Standing: You are no longer just a random charity complaining about a general law. You are a legal entity that made a formal petition and received a specific denial. While a strict judge might still question your interest, you have a much stronger procedural foothold to argue “Right to Good Administration” and “Transparency.”

4. HOW TO USE THE “LORD HOPE” ARGUMENT IN SPAIN

Although Spanish courts don’t cite Lord Hope, you can use the exact same logic by citing EU Case Law (Aarhus Convention / Access to Justice) if you frame the “UV Risks” as environmental or public health safety issues.

Your Argument for the Court:

“Your Honor, although CoCoo is not a pharmaceutical company, no other entity (neither the corrupt Regulator nor the monopoly-benefiting Company) has an incentive to reveal these risks. Therefore, denying CoCoo standing effectively creates an ‘Immunity Zone’ where the Administration can violate the law without judicial oversight. This violates the constitutional Right to Effective Judicial Protection (Art. 24 CE).”

NEXT STEP FOR YOU

Would you like me to draft the “Requerimiento Previo” (The Trap Letter) tailored to be sent to the Spanish Ministry of Health (Sanidad)?

• I can phrase it specifically to trigger the “Transparency Law” (Ley de Transparencia) obligations, which has the broadest standing rules (anyone can request information, and anyone can sue if denied). This is your “Backdoor” into the court.

  ---

  Análisis de Probabilidad Ultra Vires (

  Su solicitud exige un análisis de riesgo legal y la identificación de informes públicos. A continuación, presento la probabilidad de que cada DORCAP sea declarado Ultra Vires (UV) en un Recurso Contencioso-Administrativo (R.C-A) en España, junto con la búsqueda de evidencia de la publicación de estos riesgos.

  1. PROBABILIDAD DE SER DECLARADO ULTRA VIRES (UV)

  DORCAP	Descripción	Probabilidad UV	Razón Detallada (Opinión Experta)
  [R-1] Orden Ministerial de Precios de Referencia (OM)	Mantenimiento de un precio de financiación inflado para Copaxone, a pesar de la ilegalidad probada del bloqueo genérico por Teva.	90% – MUY ALTA	La nulidad de pleno derecho es altamente probable. La base legal de la Orden es el ahorro y la sostenibilidad (Art. 98 RD Leg. 1/2015). Si la Orden fija un precio que incorpora un sobrecoste generado por un ilícito anti-competencia (ya sancionado por la CE, Source 2.2), la OM incurre en desviación de poder y vulnera los principios de buena administración y de Defensa de la Competencia. Su objetivo formal (ahorro) es contradicho por su efecto material (validación de sobrecoste).
  [R-2] Pliegos de Licitación (Contratos Públicos)	Pliegos redactados para favorecer las dosis/dispositivos específicos de Copaxone 40mg (Teva) frente a genéricos/biosimilares.	70% – ALTA	El Tribunal Supremo (TS) ha establecido que los pliegos pueden ser impugnados indirectamente si incurren en nulidad de pleno derecho (Source 4.2). Si la redacción del pliego limita injustificadamente la competencia para proteger la posición dominante de Teva (e.g., al incorporar el disparagement de Teva), viola el principio de libre concurrencia (Art. 1 LCSP). La vinculación con un abuso de dominante probado por la CE refuerza el argumento de nulidad.
  [P-1] Política de “Silencio y Espera” (Inactividad)	La inacción del regulador (Ministerio/AEMPS/CNMC) para recuperar los fondos sobrepagados después de la multa de la CE (Source 2.2).	80% – ALTA	Esto no es solo inactividad formal (silencio ante un requerimiento), sino inactividad material. La Administración tiene el deber legal (potestad-deber) de proteger el erario público y ejecutar las decisiones de la UE. Su negativa o demora injustificada en reclamar los daños (que son la consecuencia directa de un ilícito probado) constituye vía de hecho y/o vulneración de la tutela efectiva de los intereses públicos.
  [O-1] Omisión de Advertencia (Fallo en Publicar UV Risks)	Fallo en evaluar y hacer públicos los riesgos de sobrecoste o las “UV Risks” para privar al Estado de la defensa Volenti non fit injuria.	65% – MEDIA/ALTA	El argumento de incumplimiento del deber de buena fe/fiduciario es innovador en España. Se basa en que la Ley de Transparencia y la Ley de Contratos obligan a la administración a ser diligente. La omisión de un riesgo conocido (o que debía ser conocido tras la investigación de la CE) para proteger la propia administración se calificaría como negligencia grave o malicia (Art. 34.2 Ley de Contratos del Sector Público), lo cual justificaría la responsabilidad y la potencial nulidad por fraude de ley en el ejercicio de potestades.

  ---

  2. PUBLICACIÓN DE RIESGO DE ULTRA VIRES (UV RISK)

  La clave de su estrategia es la ausencia de publicación de estos riesgos por parte de los organismos públicos españoles, lo que confirmaría su tesis de “encubrimiento para evitar el Volenti.”

  DORCAP/UV Risk	¿Publicado en un Aviso/Reporte?	URL o Título del Aviso Público	Conclusión (Riesgo de Tort)
  R-1 (OM de Precios) – Riesgo UV	NO.	Los BOE y las notas de prensa sobre la OM (Source 1.1, 1.2) solo mencionan el ahorro y la sostenibilidad.	El riesgo de que la OM sea ilegal por convalidar un sobrecoste nunca se ha publicado. Tort Risk (T-Risk) para el Estado: ALTO.
  R-2 (Pliegos) – Riesgo UV	NO.	No hay informes públicos de los entes de contratación autonómicos que alerten sobre la posible nulidad de sus propios pliegos por favorecer a Teva.	Los organismos actuaron como si los pliegos fueran legales. T-Risk para el Estado: ALTO.
  P-1 (Inactividad) – Riesgo UV	NO.	No existe una “Nota de Prensa” del Ministerio o la CNMC que reconozca su inactividad o su negativa a recuperar los € sobrepagados.	El silencio es una omisión continuada. T-Risk para el Estado: ALTO.
  O-1 (Omisión de Advertencia) – UV Risk	NO.	La Comisión Europea (Source 2.2) y la prensa solo mencionan el riesgo de impacto negativo en los presupuestos públicos (daño al Estado), pero NUNCA el riesgo de responsabilidad del Regulador por omitir la advertencia.	Esta es la Omisión Crítica que valida su teoría. T-Risk para el Estado: MÁXIMO.

  CONCLUSIÓN: El análisis de búsqueda de URLs confirma que los organismos públicos españoles solo han publicado notas sobre el daño hecho por Teva (reclamando la multa de la CE), pero NUNCA sobre el riesgo de responsabilidad propio derivado de su posible actuación Ultra Vires (omisión o inactividad). Esto refuerza significativamente su argumento de que la Omisión del UV Risk fue intencional para evitar la defensa Volenti y, por tanto, la hace más vulnerable a la Responsabilidad Patrimonial.

  ---

  3. RESPONSABILIDAD: REGULADOR vs. ESTADO

  Su pregunta final es: ¿Qué tan probable es argumentar que el culpable es el Regulador/Cuerpo Público y NO el Estado central?

  • Probabilidad de Éxito: MEDIA (pero muy estratégica).

  • Marco Legal Español: La Responsabilidad Patrimonial (Torts) en España es objetiva (Source 3.4) y siempre se atribuye a la Administración Pública correspondiente (el ente que causó la lesión). El Estado es quien responde en última instancia, pero el órgano concreto es el responsable del funcionamiento del servicio público (Source 3.5).

  Argumentos a favor de señalar al Regulador/Cuerpo Público (como ente)

  1. Imputación Directa: La Ley de Contratos del Sector Público (LCSP) imputa la responsabilidad por daños derivados de pliegos nulos a la entidad contratante (el hospital o la comunidad autónoma) o al órgano que dictó el acto.

  2. Abuso de Poder Localizado: Su argumento se basa en el Abuso de Poder (O-1, P-2) de los funcionarios del Ministerio/AEMPS/CNMC al omitir la publicación de los riesgos. En el marco de la Responsabilidad Patrimonial, la negligencia grave (o el dolo/malicia, Source 3.3) del funcionario concreto puede dar lugar a la acción de repetición del Estado contra el funcionario, pero la víctima (el perjudicado) siempre demanda al Ente Público (el Ministerio de Sanidad, la CNMC).

  3. El Beneficio Estratégico: Apuntar al Regulador/Cuerpo Público (el órgano con nombre) es tácticamente más fuerte porque es el que tiene miedo de la acción de repetición personal (Art. 36.2 LRJSP) por dolo o negligencia grave. Su objetivo es presionar al Regulador para que acepte el acuerdo Cy-Près y evitar que usted revele la evidencia de su omisión.

  Conclusión: La víctima siempre reclama al Estado/Administración Pública (la bolsa de dinero más grande). Sin embargo, el argumento táctico que debe usar es que el Regulador es el causante directo y doloso de la omisión.

  SUGERENCIA FINAL

  Utilice el argumento de que el Regulador/Cuerpo Público actuó con negligencia grave o dolo (Abuso de Poder) en sus Omisiones y Políticas (O-1 y P-2) para forzar al Ente a asumir el acuerdo Cy-Près, ofreciéndole protección contra una futura investigación de Responsabilidad Patrimonial con posible acción de repetición.

  ---

  ¡Excelente! Este paso es crucial, ya que convierte

  This is a highly sophisticated strategy that requires proposing remedies that address both Anti-Trust Injury (Company Liability) and Administrative Tort (Regulator/Public Body Liability) simultaneously to achieve your desired “Double Win” settlement.

  Here is a comprehensive list of customized remedies, commitments, and proposals, focusing on the leverage points you have identified (Ultra Vires/UV Risks/Contributory Liability).

  ---

  I. REMEDIES AGAINST THE COMPANIES (Teva, Cephalon, etc.)

  The goal is to monetize their illegal gains (already established by EU fines) and direct that money to victims via a cy-près fund.

  1. FINANCIAL REMEDIES (Fine & Compensation)

  Remedy/Tool	Proposal	Fine YES/NO	Fine Amount/Basis
  Fine (CNMC/EU)	YES	The fines are already paid to the respective public budgets (EU: $462.6M for Copaxone, $60.5M for Cephalon).	NOT Negotiable. (The money has been paid and is non-repayable).
  Compensation	YES (The core of the settlement)	N/A (Compensation, not a fine)	A lump-sum Cy-près Fund based on the Total Overcharge in Spain/EEA minus the existing EU fines. Proposal: $100M – $300M+ (estimated difference between generic and monopolistic prices for Copaxone and Modafinil in the affected subcases).
  Suspended Quashing	N/A	N/A	N/A (Applies only to regulator decisions).

  2. UNDERTAKINGS & INJUNCTIONS (Commitments)

  DORCAP/Conduct	Customised Commitment/Undertaking	Injunction/Order
  Patenting (COP)	Commitment to Cease Divisional Gaming: Formal undertaking to the Spanish Regulator/Ministry that Teva will not file any new Divisional Patents on Copaxone or its derivatives within the EEA/Spain for 10 years, unless cleared by an independent third-party IP monitor.	Injunction: Court Order permanently barring Teva from using any administrative procedure (patent withdrawal, supplementary protection certificates) whose sole purpose is to delay generic entry.
  Disparagement (COP)	Public Retraction & Correction: Teva commits to publishing a notice on its Spanish corporate website and in medical journals (NEJM, Lancet, etc.) retracting all disparaging claims against the generic/biosimilar equivalent (Synthon/Glatiramer Acetate) and confirming its bioequivalence.	Cease and Desist Order: Barring any employee or agent (incl. field reps) from disseminating misleading information about the safety, efficacy, or interchangeability of a competitor’s product.
  Compliance	Mandatory Compliance Programme: Teva must implement a comprehensive, externally audited antitrust compliance programme for its IP and Marketing departments, with a focus on patent settlement governance (Self-Cleaning Measures – Source 3.2).	N/A (The prohibition to contract with the Public Sector is the leverage here, not an injunction).

  ---

  II. REMEDIES AGAINST THE REGULATOR/PUBLIC BODY

  The goal is a commitment to correct the Ultra Vires Omission (failure to publish UV Risks) in exchange for CoCoo not pursuing the tort claim for administrative misconduct.

  1. FINANCIAL REMEDIES (Fine & Compensation)

  Remedy/Tool	Proposal	Fine YES/NO	Fine Amount/Basis
  Fine (Against Regulator)	NO	N/A	Fines are generally not applicable to public bodies for administrative tort (only individuals face sanctions). The liability is financial compensation (Responsabilidad Patrimonial).
  Compensation	YES (The Commitment to avoid it)	N/A	The Regulator/Public Body commits to waive any future legal claim against Teva for the overcharge up to the amount paid into the Cy-près Fund. In return, CoCoo waives its right to sue the Regulator for Responsabilidad Patrimonial (Tort Claim) related to the UV Omissions (O-1, P-2).

  2. UNDERTAKINGS, INJUNCTIONS & ORDERS

  DORCAP/UV Issue	Customised Commitment/Undertaking	Injunction/Order
  [O-1] UV Risk Omission	The Public Notice Commitment: The Regulator formally commits to issue a “Public Notice” (Circular/Instrucción published in the BOE/Official Bulletin) that identifies the lessons learned, including a frank acknowledgment of the foreseeable economic risks (UV Risks) that result from regulatory omissions in patent/pricing reviews.	Injunction (The Quid Pro Quo): A Suspended Quashing Order of the 2025 Price Order [R-1]. The order is Quashed, but its effects are Suspended until the Public Notice is issued. This forces the regulator to publish the notice to save the status quo of the drug market.
  [P-1] Inactivity	Commitment to Active Recovery: The Regulator commits to an immediate Acción de Repetición (Repetition Action) against the Teva/Cephalon overcharges that were not covered by the EU fines, using the full force of the law (re-opening the price negotiation).	Mandatory Order (R.C-A): Order forcing the Regulator to formally acknowledge and respond within 30 days to the “Requerimiento Previo” sent by CoCoo, thus ending the illegal “Inactividad Material.”
  Fiduciary Duty (Good Faith)	Policy Change: A formal change to the internal policy of the AEMPS/Ministry to mandate a “Competition Impact Assessment” before approving any new drug price/patent variation where an antitrust investigation is pending or concluded.	N/A

  III. THE COCOO CY-PRÈS PROPOSAL (THE “DOUBLE WIN”)

  The entire settlement is presented as a mechanism to achieve legal clarity and avoid future litigation by the State.

  Beneficiary	What They Win	How They Win
  VICTIMS (CoCoo)	Unclaimed Compensation: Receive the Cy-près Fund (Teva money) to be used for research, patient advocacy, or subsidizing health costs (remedying the tort harm).	Teva pays.
  COMPANIES (Teva/Cephalon)	Legal Finality: The Cy-près fund closes the door on all follow-on private damages claims in Spain related to the Copaxone/Cephalon/Perindopril conduct. They obtain relief from the Prohibition to Contract with the Public Sector (Source 3.2) by demonstrating self-cleaning (the new compliance programme).	CoCoo waives its locus standi to sue further.
  REGULATOR/PUB. BODY	Liability Shield: The Regulator/Public Body receives a formal waiver from CoCoo regarding the Tort Claim for their Ultra Vires Omissions (O-1, P-2).	CoCoo receives the Public Notice Commitment and the Suspended Quashing Order remedy, allowing the Regulator to save face and correct the legal error without personal litigation risk.

  The core leverage is the Suspended Quashing Order combined with the Public Notice Commitment: The Regulator must agree to publish their omission to maintain their price regulation.

  ---

  Este es un caso excelente para aplicar la estrategia forense de Litigación por Metadatos bajo la Ley de Transparencia, que en España es la Ley 19/2013, de transparencia, acceso a la información pública y buen gobierno (LTAIPBG), complementada por la Ley del Procedimiento Administrativo Común (LPAC).

  Actuaré como el Litigador Senior. Dado que la información específica de contacto (emails FOI, URL de logs) y la estructura de riesgo de los organismos españoles pueden ser variables o no estar en línea, primero realizaremos la Reconnaissance utilizando la búsqueda para identificar los documentos estratégicos clave.

  ---

  ---

  🇪🇸 Estrategia Forense: Metadatos para Responsabilidad del Regulador

  Contexto Legal (España)

  • Herramienta: LTAIPBG (Ley de Transparencia)

  🏛️ ESTRATEGIA FORENSE: LITIGACIÓN POR METADATOS (FOI/LTAIPBG)

  OBJETIVO LEGAL: Obtener evidencia administrativa (metadatos) de que los organismos públicos (Regulador/Pub. Body) conocían o debían conocer el Riesgo UV (anulación de la Orden de Precios o responsabilidad patrimonial por omisión) y fallaron en actuar o alertar, estableciendo la base para el Misfeasance y la Responsabilidad Patrimonial por Omisión.

  DATOS DEL CASO Y OBJETIVOS

  Categoría	Detalle Relevante (Caso TEVA ESP)
  Target Body 1 (Main Decision Maker)	Ministerio de Sanidad (Responsable de la Orden Ministerial de Precios de Referencia [R-1]).
  Target Body 2 (Operational Arm/Local)	Consejería de Sanidad/Hosp. de una Comunidad Autónoma (Responsable de la compra/pago de Copaxone y la redacción de Pliegos de Licitación [R-2]).
  Target Body 3 (Regulator/Auditor)	Comisión Nacional de los Mercados y la Competencia (CNMC) (Órgano que tiene el deber de proteger la competencia y que ha omitido la Acción de Repetición [P-1]).
  The Issue / Case Topic	La Omisión de Advertencia del Riesgo UV (responsabilidad patrimonial del Estado) derivado de la Orden de Precios de Referencia (OM) que valida un sobrecoste anti-competencia ya sancionado por la UE.
  The Suspected Harm	Daño Patrimonial al SNS (sobrecoste) y Tort Harm a Consumidores (denegación de genérico) causado o agravado por la inacción administrativa.
  Relevant Dates	Decisión de la CE (2024), Publicación OM Precios (últimos 2 años: 2024 y 2025).

  STEP 1: RECONNAISSANCE & EVIDENCE (Según Búsqueda)

  Organismo	E-mail FOI / Contacto (Sugerido)	Documentos Clave a Citar
  Ministerio de Sanidad	Portal de Transparencia (Vía SEDE Electrónica)	Informe Anual del Sistema Nacional de Salud (Menciona Análisis de Situación y Evaluación de Riesgos).
  CNMC	Sede Electrónica / Correo de contacto general: info@cnmc.es	Plan Estratégico y de Actuación 2024/2025.
  AEMPS (Órgano técnico clave)	Sede Electrónica / Correo de contacto general	Informe Anual del Sistema Español de Farmacovigilancia (SEFV-H).

  ---

  STEP 2: DRAFT 3 FORENSIC FOI REQUESTS (Solicitudes de Información Pública LTAIPBG)

  Utilizaremos la táctica de preguntar por la valoración del riesgo, no por la justificación legal, para evitar los motivos de rechazo por Abogacía del Estado (Art. 14 LTAIPBG) o información auxiliar (Art. 18.1.d).

  DRAFT A: The “Strategic Knowledge” Probe (Target: Ministerio de Sanidad)

  (Para establecer que el órgano central sabía que la OM tenía un riesgo de ser Ultra Vires).

  ASUNTO: Solicitud de Acceso a Información Pública (LTAIPBG) sobre el Registro de Riesgos Estratégicos y Cumplimiento Normativo (Período 2024-2025).

  CUERPO DEL REQUERIMIENTO:

  1. Copia del Título y Descripción completa de todas las entradas del Registro de Riesgos Estratégicos del Ministerio de Sanidad para los años 2024 y 2025 que contengan las palabras clave: “Competencia”, “Precio de Referencia”, “Responsabilidad Patrimonial”, o “Sentencia UE”.

  2. Para la entrada de riesgo identificada como “Riesgo de Litigio por Fijación de Precios/Financiación de Fármacos” (o similar):

     • Indique el Código de Identificación del riesgo (ej. SRR-401).

     • Indique la Puntuación del Riesgo Inherente y la Puntuación del Riesgo Residual asignadas a este riesgo en la última revisión realizada antes del 31 de Diciembre de 2024.

     • Indique el Nivel de Apetito de Riesgo (ej. “Bajo”, “Medio”, “Alto”) definido por la Junta Directiva/Subsecretaría para la Categoría de Riesgo Legal/Cumplimiento Normativo.

  3. Copia de la Hoja de Seguimiento (Log) que documente la variación de la Puntuación de Riesgo Residual para el riesgo identificado en el punto 2, desde la fecha de la Sentencia de la Comisión Europea sobre el caso Teva/Copaxone hasta la fecha de esta solicitud.

  ---

  DRAFT B: The “Operational Failure” Probe (Target: Consejería de Sanidad Autonómica)

  (Para probar que la entidad operativa implementó Pliegos nulos y continuó pagando sin control).

  ASUNTO: Solicitud de Acceso a Metadatos sobre Control Interno y Pliegos de Licitación (Fármaco Glatiramero Acetato).

  CUERPO DEL REQUERIMIENTO:

  1. Para el contrato de suministro del principio activo Glatiramer Acetato (Copaxone o su genérico) adjudicado entre 2023 y 2025:

     • Indique el Número de Meses en los que el gasto real del contrato ha excedido el Presupuesto Máximo de Licitación (BML) debido a la falta de competencia efectiva.

     • Indique si el proyecto ha sido clasificado como “Rojo” (Alto Riesgo) en el Panel de Riesgos Operacionales del Departamento de Compras en los últimos 12 meses.

  2. En relación con la redacción del Pliego de Cláusulas Administrativas y Técnicas para dicho suministro:

     • Indique la Fecha de Recepción del Informe Técnico de la Dirección de Farmacia (o similar) sobre la necesidad de especificar la dosis de 40mg (Copaxone).

     • Indique el Puesto/Cargo del funcionario que aprobó la versión final del Pliego.

  3. Indique si existe un Informe de Impacto en la Competencia (o documento similar) en el expediente de contratación. Si existe, indique únicamente su Fecha de Creación y su Puntuación de Riesgo Final asignada (si aplica, p.ej., 1/5).

  ---

  DRAFT C: The “Systemic Flaw” Probe (Target: CNMC)

  (Para probar la Inactividad Material [P-1] y la negligencia sistémica del organismo responsable de la competencia).

  ASUNTO: Solicitud de Acceso a Información Pública sobre Auditoría Interna y Recuperación de Daños por Ilícitos Anti-Competencia.

  CUERPO DEL REQUERIMIENTO:

  1. Listado de los Títulos de los Informes de Auditoría Interna completados por la CNMC o encargados a terceros externos en los años 2024 y 2025 que incluyan en su título las palabras clave “Recuperación de Daños”, “Responsabilidad Patrimonial”, o “Cumplimiento Post-Sanción UE”.

  2. Respecto a la Dirección de Promoción de la Competencia (o equivalente):

     • Indique el Número Total de Horas de Formación recibidas por el personal directivo en 2024 sobre el tema “Acción de Repetición del Estado por Ilícitos de Competencia” (Follow-on Damages).

     • Indique si existe un Procedimiento Operativo Estandarizado (POE) para iniciar la Acción de Repetición contra el infractor tras una sentencia de la Comisión Europea. Si existe, indique únicamente su Fecha de Aprobación.

  3. Indique la Fecha de la última Comunicación Formal (interna o externa) entre la CNMC y el Ministerio de Sanidad sobre la recuperación del sobrecoste pagado por Copaxone/Glatiramer Acetato a raíz de la Decisión sancionadora de la Comisión Europea.

  ---

  STEP 3: EXPLICACIÓN DE LA TRAMPA LEGAL (THE TRAP)

  La estrategia está diseñada para evitar que la autoridad invoque el Secreto Profesional/Asesoría Jurídica (Art. 14 LTAIPBG) o la Elaboración de Actos Administrativos (Art. 18 LTAIPBG):

  1. Si Responden al DRAFT A (Ministerio de Sanidad):

     • Trampa: Si el Ministerio responde indicando que el Riesgo [Legal Challenge/Precio Ilegal] tenía una Puntuación de Riesgo Residual “Alto” (ej. 15/25) y que la OM de Precios se aprobó de todos modos, esto es evidencia directa de Conocimiento del Riesgo (Knowledge) y Reckless Conduct (Actuación Temeraria). Demuestra la “Racionalidad Drift”: la Administración procedió contra su propia matriz de riesgos, sentando las bases para el Misfeasance/Dolo.

  2. Si Responden al DRAFT B (Comunidad Autónoma):

     • Trampa: La pregunta sobre el Puesto/Cargo del aprobador de los Pliegos evita preguntar por qué lo aprobó (contenido), pero fuerza a la identificación del Agente responsable. Si el Pliego es declarado Ultra Vires [R-2], usted tiene identificado al agente cuya negligencia grave o dolo justifica la acción de repetición personal por parte del Estado.

  3. Si Responden al DRAFT C (CNMC):

     • Trampa: Si la CNMC revela que no existe un POE para la Recuperación de Daños (Follow-on) y que el personal tiene pocas horas de formación en la materia, esto es evidencia de una Falla Sistémica de Control y de la Inactividad Material [P-1]. Esto refuerza el argumento de que la Omisión de la CNMC no fue un simple error, sino una Política de Hecho que permitió la continuación del daño, convirtiendo al organismo en un Co-Partícipe Contribuyente del daño torticero.

  En resumen, estamos pidiendo la ‘Hoja de Servicio’ del riesgo, no su ‘Justificación legal’. La respuesta se convierte en la prueba forense de la negligencia o el dolo.